CybroCell™
Degenerative Disc Disease (DDD)
Phase I / IIFDA IND Cleared
Key Facts
Indication
Degenerative Disc Disease (DDD)
Phase
Phase I / II
Status
FDA IND Cleared
Company
About FibroBiologics
FibroBiologics is a clinical-stage biotech focused on developing fibroblast cell-based therapies for chronic diseases, positioning fibroblasts as a superior alternative to mesenchymal stem cells. The company has established a robust intellectual property portfolio of over 270 patents and has achieved an FDA IND clearance for its lead program in Degenerative Disc Disease. Its strategy hinges on demonstrating clinical proof-of-concept for its fibroblast platform across multiple high-need indications to validate its core technological thesis and unlock significant value.
View full company profileTherapeutic Areas
Other Degenerative Disc Disease (DDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| SB-01 | Spine BioPharma | Phase 3 |